Vion Pharmaceuticals was founded in 1992 and is based in New Haven, Connecticut. On December 17, 2009, Vion Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. Vion Pharmaceuticals, Inc., a development-stage pharmaceutical company, develops and commercializes therapeutics for the treatment of cancer. It has two agents in clinical trials, Onrigin and Triapine. Onrigin, a novel alkylating agent that damages DNA to prevent cancer cells from reproducing, is in various clinical trials for the treatment of various indications, such as acute myeloid leukemia (AML), relapsed AML, de novo poor-risk, small cell lung cancer, brain tumors, myelodysplastic syndromes, chronic lymphocytic leukemia, hematologic malignancies, and solid tumors. Triapine is a small molecule in various clinical trials to prevent the replication of tumor cells by blocking a critical step in DNA synthesis. Vion company's other products and product candidates include MELASYN, a water-soluble, synthetic version of melanin for formulation of skin care products and cosmetics; and Nucleoside Analogs, known as elvucitabine, which is in Phase II clinical trials as an antiviral drug for the treatment of human immunodeficiency virus.

Pfizer Limited company is the top provider of medicines to the UK's National Health Service, offering many of its parent company's products to treat conditions including cardiovascular ailments and cancers. It also provides animal health products. Pfizer Limited conducts research and development activities, focusing on medications in the areas of allergy, respiratory, urinary, metabolic, and gastrointestinal ailments, as well as vaccines, anti-retrovirals, and pain treatments.

CytRx Corporation company was founded in 1985 and is headquartered in Los Angeles, California. CytRx Corporation, a biopharmaceutical research and development company, engages in the development of human therapeutics. Its product pipeline includes Tamibarotene, a synthetic retinoid in Phase II clinical development to treat acute promyelocytic leukemia; INNO-2006, a pro-drug for doxorubicin in Phase II clinical development for the treatment of cancer; Bafetinib, a drug in Phase I clinical development to treat chronic myeloid leukemia; Arimoclomol, an orally-administered small-molecule product candidate in Phase IIb clinical development for the treatment of amyotrophic lateral sclerosis; and Iroxanadine, an orally-administered small-molecule product candidate in Phase I clinical development to treat diabetic ulcers. The company also engages in developing treatments for neurodegenerative and other disorders based on its small-molecule molecular chaperone amplification technology; and new-drug discovery research utilizing its master chaperone regulator assay technology.

Novartis Pharmaceuticals holds down the fort on this side of the big pond. As the US pharmaceuticals marketing affiliate of Swiss drug giant Novartis AG, the company helps with the development and sales of its parent company's products in the US. Its product line addresses a range of ailments including cardiovascular and respiratory diseases, gastrointestinal complaints, central nervous system disorders, cancer and blood disorders, bone and joint conditions, and organ transplants. Key products include tumor growth inhibitor Gleevec, high blood pressure drug Diovan, and attention deficit disorder therapies Focalin and Ritalin.

StemCells, Inc. company was founded in 1988 and is based in Palo Alto, California. StemCells, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of cell-based therapeutics to treat damage to, or degeneration of, major organ systems. The Company has two product development programs: CNS Program, which is developing applications for its human neural stem cell and Liver Program, which is developing applications for its human liver engrafting cells. In addition, it is conducting preclinical work for spinal cord injury, myelin disorders and retinal disorders. In December 2008, the Company received authorization from the United States Food and Drug Administration (FDA) to initiate a Phase I clinical trial of its HuCNS-SC cells in a second indication, Pelizeaus-Merzbacher Disease (PMD), a fatal myelination disorder in the brain. In April 2009, StemCells, Inc. completed the acquisition of substantially all of the operating assets and liabilities of Stem Cell Sciences Plc.

Immunomedics, Inc. company was founded in 1982 and is headquartered in Morris Plains, New Jersey. Immunomedics, Inc. (Immunomedics) is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. The Company has developed a number of advanced technologies that allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create targeted agents. Immunomedics has licensed its product candidate epratuzumab, to UCB S.A. (UCB), for the treatment of all autoimmune disease indications worldwide. Epratuzumab’s most advanced clinical testing is for the treatment of systemic lupus erythematosus (SLE), and in non-Hodgkin’s lymphoma (NHL). The Company has antibody product candidates in clinical development targeting B-cell NHL, other B-cell mediated diseases and various solid tumors.

Cortex Pharmaceuticals develops drugs to treat neurodegenerative and psychiatric disorders. Its research focuses on the AMPA receptor, which facilitates communication between nerve cells; the firm's Ampakine compounds may enhance this receptor's activity. Its lead drug candidate is CX717, which it is developing for a number of indications including respiratory depression (a potentially fatal side effect of some anesthetics and post-surgical painkillers), Alzheimer's disease, attention deficit hyperactivity disorder (ADHD), and daytime sleepiness. The firm believes Ampakine drugs may also be helpful in treating a variety of other brain-related disorders, including depression, autism, and Huntington's disease.

Obagi Medical Products, Inc. company was founded in 1988 and is headquartered in Long Beach, California. Obagi Medical Products, Inc. is a specialty pharmaceutical company focused on the aesthetic and therapeutic skin health markets. The Company develops and commercializes prescription-based products, topical skin health systems that enable physicians to treat a range of skin conditions, including pre-mature aging, photo-damage, hyperpigmentation (irregular or patchy discoloration of the skin), acne, rosacea and soft tissue deficits, such as fine lines and wrinkles. The Company markets and sells a range of systems and related products for the enhancement of skin health. Its principal product line is its Obagi Nu-Derm System. Its Obagi Nu-Derm System is a prescription-based topical skin health system that enhances the skin's overall health by correcting photo damage using drugs that, by definition, work at the cellular level, resulting in a reduction of the visible signs of aging. In January 2009, the Company launched the Obagi Rosaclear System.

Dechra lies down with dogs ... and cats and birds and horses too. Dechra Pharmaceuticals lays claim to being the only listed pharmaceutical company that makes most of its income from the animal health care market. The company manufactures and distributes veterinary pharmaceutical products and supplies internationally, mainly in the US and the UK. Its network of subsidiaries includes suppliers National Veterinary Services and Dechra Veterinary Products, manufacturer Dales Pharmaceuticals, and development companies North Western Laboratories and Cambridge Specialist Laboratory Services.

Nutraceutical International Corp. was founded in 1993 and is based in Park City, Utah. Nutraceutical International Corporation engages in the manufacture, marketing, distribution, and retail of branded nutritional supplements and other natural products in the United States and internationally. The company offers vitamins and minerals, herbs, specialty formulas, personal care products, homeopathics, functional foods, and other products in various formulations and delivery forms, including capsules, tablets, softgels, chewables, liquids, creams, sprays, powders, and whole herbs. It also publishes, prints, and markets a line of books and booklets to book distributors, national retail bookstores, and health and natural food stores; distributes branded products of certain third parties; and owns neighborhood natural food markets and health food stores. Nutraceutical International sells its products primarily to and through domestic health and natural food stores.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.